• +1-646-491-9876
    • +91-20-67278686

    Search

    Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2017

    Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2017

    • Report Code ID: RW0001709433
    • Category Pharmaceuticals
    • No. of Pages 136
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.

    Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 1, 23, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

    Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology) .
    - The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Chemotherapy Induced Peripheral Neuropathy - Overview 8
    Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 13
    Products under Development by Companies 14
    Products under Development by Universities/Institutes 16
    Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment 17
    Assessment by Target 17
    Assessment by Mechanism of Action 20
    Assessment by Route of Administration 23
    Assessment by Molecule Type 25
    Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development 27
    Achelios Therapeutics Inc 27
    Advinus Therapeutics Ltd 27
    Apollo Endosurgery Inc 28
    Aptinyx Inc 28
    Asahi Kasei Pharma Corp 29
    Can-Fite BioPharma Ltd 29
    Celgene Corp 30
    DermaXon LLC 30
    Eisai Co Ltd 31
    Immune Pharmaceuticals Inc 31
    INSYS Therapeutics Inc 32
    Kineta Inc 32
    KPI Therapeutics Inc 33
    Krenitsky Pharmaceuticals Inc 33
    MAKScientific LLC 34
    Metys Pharmaceuticals AG 34
    Midatech Pharma US Inc 35
    Mundipharma International Ltd 35
    Nemus Bioscience Inc 36
    Neurocentrx Pharma Ltd 36
    Panacea Pharmaceuticals Inc 37
    PeriphaGen Inc 37
    PharmatrophiX Inc 38
    PledPharma AB 38
    Sova Pharmaceuticals Inc 39
    Virobay Inc 39
    WEX Pharmaceuticals Inc 40
    Chemotherapy Induced Peripheral Neuropathy - Drug Profiles 41
    (amitriptyline + ketamine hydrochloride) - Drug Profile 41
    ACY-1083 - Drug Profile 45
    AM-1710 - Drug Profile 46
    APX-2009 - Drug Profile 48
    APX-3330 - Drug Profile 49
    BR-297 - Drug Profile 52
    cannabidiol - Drug Profile 53
    dimiracetam - Drug Profile 56
    Drugs for Peripheral Neuropathy - Drug Profile 58
    DX-0332 - Drug Profile 59
    E-2072 - Drug Profile 60
    HM-01 - Drug Profile 61
    KCP-400 - Drug Profile 62
    ketoprofen - Drug Profile 63
    KP-544 - Drug Profile 64
    KRN-5500 - Drug Profile 65
    LM-11A31BHS - Drug Profile 69
    Lpathomab - Drug Profile 71
    MR-309 - Drug Profile 74
    NB-2111 - Drug Profile 76
    NRX-2922 - Drug Profile 77
    NT-24336 - Drug Profile 78
    PAN-811 - Drug Profile 79
    PGN-503 - Drug Profile 81
    piclidenoson - Drug Profile 82
    pirenzepine hydrochloride - Drug Profile 92
    PP-095 - Drug Profile 93
    Q-201 - Drug Profile 97
    ricolinostat - Drug Profile 98
    Small Molecule to Inhibit Cystathionine Gamma Lyase for Inflammatory Pain and Chemotherapy Induced Peripheral Neuropathy - Drug Profile 106
    Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 107
    Small Molecules for Pain - Drug Profile 108
    Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 109
    Small Molecules to Block Nav 1.8 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 110
    Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile 111
    Tetrodotoxin - Drug Profile 112
    thrombomodulin alfa - Drug Profile 114
    U-2902 - Drug Profile 116
    VBY-036 - Drug Profile 118
    XEN-106 - Drug Profile 120
    XT-150 - Drug Profile 121
    Chemotherapy Induced Peripheral Neuropathy - Dormant Projects 122
    Chemotherapy Induced Peripheral Neuropathy - Discontinued Products 124
    Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones 125
    Featured News & Press Releases 125
    Appendix 132
    Methodology 132
    Coverage 132
    Secondary Research 132
    Primary Research 132
    Expert Panel Validation 132
    Contact Us 132
    Disclaimer 133

    List of Tables

    Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Advinus Therapeutics Ltd, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Apollo Endosurgery Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Pharma Corp, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Can-Fite BioPharma Ltd, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Celgene Corp, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by DermaXon LLC, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co Ltd, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by INSYS Therapeutics Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by KPI Therapeutics Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific LLC, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Metys Pharmaceuticals AG, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Midatech Pharma US Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mundipharma International Ltd, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Neurocentrx Pharma Ltd, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Virobay Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2017
    Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Achelios Therapeutics Inc
    Advinus Therapeutics Ltd
    Apollo Endosurgery Inc
    Aptinyx Inc
    Asahi Kasei Pharma Corp
    Can-Fite BioPharma Ltd
    Celgene Corp
    DermaXon LLC
    Eisai Co Ltd
    Immune Pharmaceuticals Inc
    INSYS Therapeutics Inc
    Kineta Inc
    KPI Therapeutics Inc
    Krenitsky Pharmaceuticals Inc
    MAKScientific LLC
    Metys Pharmaceuticals AG
    Midatech Pharma US Inc
    Mundipharma International Ltd
    Nemus Bioscience Inc
    Neurocentrx Pharma Ltd
    Panacea Pharmaceuticals Inc
    PeriphaGen Inc
    PharmatrophiX Inc
    PledPharma AB
    Sova Pharmaceuticals Inc
    Virobay Inc
    WEX Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//chemotherapy-induced-peripheral-neuropathy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//chemotherapy-induced-peripheral-neuropathy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//chemotherapy-induced-peripheral-neuropathy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments